ArticleBMC microbiology2024
Purified α-Amylase from Bacillus cereus exhibits antibiofilm and antiquorum sensing activities against uropathogenic Escherichia coli, Downregulating fimH, and papC virulence genes: implications for urinary tract infections.
Article in BMC microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Bladder adaptive hydrogel scaffold with dual release, antimicrobial, immunomodulatory, and repair: DRIVER for urinary tract infections.Acta pharmaceutica Sinica. B · 2026Article
- Adhesin genes expression among carbapenem-resistant uropathogenic Escherichia coli exposed to linalool and metformin.Molecular biology reports · 2025Article
- α-Amylase-Mediated Antibiotic Degradation and Sequestration inAntibiotics (Basel, Switzerland) · 2025Article
- Bacillus cereus-derived α-amylase disrupts biofilm formation and quorum sensing in multidrug-resistant Klebsiella pneumoniae.BMC microbiology · 2025Article
- Exploring Virulence Characteristics of ClinicalMicroorganisms · 2025Article
- Characterization and purification of Pseudomonas aeruginosa phages for the treatment of canine infections.BMC microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimPathogenic Escherichia coli is a known harmful microorganism that takes advantage of favorable conditions to cause various infections in healthcare settings, such as bloodstream infections related to catheters, as well as infections in the urinary and respiratory tracts. E. coli utilizes biofilm development as a means to enhance its virulence and pathogenicity. This work aims to investigate the antibiofilm activity of α-amylase enzyme against uropathogenic E. coli (UPEC) and its effect on biofilm-regulatory genes. METHODOLOGY: In this study, we evaluated the antibiofilm activity of α-amylase enzyme by spectrophotometric microtiter plate analysis and confocal laser scanning microscopy. Also, the antibacterial activity of the test enzyme was evaluated by measuring the MIC and MBC levels against UPEC. The quorum-quenching activity of α-amylase enzyme was assessed using a qRT-PCR to evaluate the impact on biofilm-regulatory genes.
resultsBased on our results, purified α-amylase showed MIC and MBC levels ranged between 128 and 512 µg /ml against UPEC isolates using broth microdilution assay. Crystal violet assay revealed MBIC of 128 µg/ml and MBEC of 256 µg/ml for the purified α-amylase. When the biofilm was analyzed by confocal laser scanning microscope, our results showed inhibition of biofilm thickness (56%) and live/dead cell percentages (43/55%). Furthermore, analysis of the effect on the expression of biofilm-encoding genes showed downregulation of both fimH and papC genes by 57 and 25%, respectively, upon treatment of UPEC with ½ of the MIC (64 µg/ml).
conclusionsThe results demonstrate that our purified α-amylase from B. cereus exhibits promising antibiofilm activities against UPEC at both phenotypic as well as genotypic levels. These findings suggest that this enzyme may serve as a natural effective tool for removing bacterial biofilms, potentially offering new therapeutic avenues for treating infections caused by UPEC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.